Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment

Abraham, 2002, Identification of TOR signaling complexes: more TORC for the cell growth engine, Cell, 111, 9, 10.1016/S0092-8674(02)01009-7 Avdulov, 2004, Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells, Cancer Cell, 5, 553, 10.1016/j.ccr.2004.05.024 Baker, 2005, Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation, Cell Cycle, 4, 330, 10.4161/cc.4.2.1485 Bamford, 2004, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br. J. Cancer, 91, 355, 10.1038/sj.bjc.6601894 Bauer, 2007, KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway, Oncogene, 26, 7560, 10.1038/sj.onc.1210558 Beeram, 2007, Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling, Ann. Oncol., 18, 1323, 10.1093/annonc/mdm170 Berns, 2007, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer, Cancer Cell, 12, 395, 10.1016/j.ccr.2007.08.030 Beuvink, 2005, The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation, Cell, 120, 747, 10.1016/j.cell.2004.12.040 Bjornsti, 2004, The TOR pathway: a target for cancer therapy, Nat. Rev. Cancer, 4, 335, 10.1038/nrc1362 Blume-Jensen, 2001, Oncogenic kinase signalling, Nature, 411, 355, 10.1038/35077225 Bortul, 2003, Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation, Leukemia, 17, 379, 10.1038/sj.leu.2402793 Brass, 1997, Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma, Hum. Mol. Genet., 6, 33, 10.1093/hmg/6.1.33 Brown, 1994, A mammalian protein targeted by G1-arresting rapamycin–receptor complex, Nature, 369, 756, 10.1038/369756a0 Broxterman, 2007, Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma, Drug Resist. Update, 10, 182, 10.1016/j.drup.2007.07.001 Bruwer, 1954, Surface pigmentation and generalized intestinal polyposis (Peutz–Jeghers syndrome), Proc. Staff Meet. Mayo Clin., 29, 168 Campbell, 2001, Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance, J. Biol. Chem., 276, 9817, 10.1074/jbc.M010840200 Cantley, 2002, The phosphoinositide 3-kinase pathway, Science, 296, 1655, 10.1126/science.296.5573.1655 Castellvi, 2006, Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer, Cancer, 107, 1801, 10.1002/cncr.22195 Chan, 2005, Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer, J. Clin. Oncol., 23, 5314, 10.1200/JCO.2005.66.130 Chen, 2004, Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome, J. Surg. Oncol., 86, 22, 10.1002/jso.20037 Chen, 2001, Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer, Oncogene, 20, 6073, 10.1038/sj.onc.1204736 Chiu, 1994, RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex, Proc. Natl. Acad. Sci. U.S.A., 91, 12574, 10.1073/pnas.91.26.12574 Chollet, 2006, Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer, Clin. Breast Cancer, 7, 336, 10.3816/CBC.2006.n.047 Cichowski, 2001, NF1 tumor suppressor gene function: narrowing the GAP, Cell, 104, 593, 10.1016/S0092-8674(01)00245-8 Clark, 2002, Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells, Mol. Cancer Ther., 1, 707 Cloughesy, 2008, Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma, PLoS Med., 5, e8, 10.1371/journal.pmed.0050008 Couch, 1999, Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer, Cancer Res., 59, 1408 Crew, 2000, Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression, Br. J. Cancer, 82, 161, 10.1054/bjoc.1999.0894 Cui, 2006, Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance, Cancer Res., 66, 5950, 10.1158/0008-5472.CAN-05-3243 Datta, 1999, Cellular survival: a play in three Akts, Genes Dev., 13, 2905, 10.1101/gad.13.22.2905 DeFatta, 2003, Translational upregulation of yes accompanies eIF4E-mediated oncogenic transformation, Int. J. Oncol., 23, 1709 DeGraffenried, 2004, Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity, Clin. Cancer Res., 10, 8059, 10.1158/1078-0432.CCR-04-0035 Dengler, 2005, Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib, Leukemia, 19, 1835, 10.1038/sj.leu.2403848 Dennis, 2001, Mammalian TOR: a homeostatic ATP sensor, Science, 294, 1102, 10.1126/science.1063518 Dennis, 1996, The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases, Mol. Cell Biol., 16, 6242, 10.1128/MCB.16.11.6242 Dudkin, 2001, Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition, Clin. Cancer Res., 7, 1758 Eberle, 2002, Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1, Br. J. Cancer, 86, 1957, 10.1038/sj.bjc.6600351 Eberle, 1997, Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro, Int. J. Cancer, 71, 396, 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E Eberle, 2007, Overcoming apoptosis deficiency of melanoma-Hope for new therapeutic approaches, Drug Resist. Update, 10, 218, 10.1016/j.drup.2007.09.001 Eckstein, 2008, Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells, J. Biol. Chem., 283, 739, 10.1074/jbc.M706287200 Engelman, 2006, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nat. Rev. Genet., 7, 606, 10.1038/nrg1879 Estrela, 2006, Glutathione in cancer biology and therapy, Crit Rev. Clin. Lab Sci., 43, 143, 10.1080/10408360500523878 Faivre, 2006, Current development of mTOR inhibitors as anticancer agents, Nat. Rev. Drug Discov., 5, 671, 10.1038/nrd2062 Fang, 2006, A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability, J. Cell Physiol., 209, 261, 10.1002/jcp.20749 Fang, 2005, Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways, FASEB J., 19, 342, 10.1096/fj.04-2175com Feng, 2005, The coordinate regulation of the p53 and mTOR pathways in cells, Proc. Natl. Acad. Sci. U.S.A., 102, 8204, 10.1073/pnas.0502857102 Fraser, 2008, Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function, Int. J. Cancer, 122, 534, 10.1002/ijc.23086 Frogne, 2005, Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth, Endocr. Relat. Cancer, 12, 599, 10.1677/erc.1.00946 Frost, 2004, In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model, Blood, 104, 4181, 10.1182/blood-2004-03-1153 Fojo, 2007, Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs, Drug Resist. Update, 10, 59, 10.1016/j.drup.2007.02.002 Fukuchi-Shimogori, 1997, Malignant transformation by overproduction of translation initiation factor eIF4G, Cancer Res., 57, 5041 Gagnon, 2004, AKT involvement in cisplatin chemoresistance of human uterine cancer cells, Gynecol. Oncol., 94, 785, 10.1016/j.ygyno.2004.06.023 Galanis, 2005, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study, J. Clin. Oncol., 23, 5294, 10.1200/JCO.2005.23.622 Gao, 2004, G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells, Am. J. Physiol. Cell. Physiol., 287, C281, 10.1152/ajpcell.00422.2003 Gao, 2004, Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells, Mol. Cell Biochem., 255, 33, 10.1023/B:MCBI.0000007259.65742.16 Gao, 2002, Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling, Nat. Cell Biol., 4, 699, 10.1038/ncb847 Garnett, 2004, Guilty as charged: B-RAF is a human oncogene, Cancer Cell, 6, 313, 10.1016/j.ccr.2004.09.022 Garnett, 2005, Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization, Mol. Cell, 20, 963, 10.1016/j.molcel.2005.10.022 Granville, 2006, Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway, Clin. Cancer Res., 12, 679, 10.1158/1078-0432.CCR-05-1654 Grolleau, 2000, Defect in the regulation of 4E-BP1 and 2, two repressors of translation initiation, in the retinoid acid resistant cell lines, NB4-R1 and NB4-R2, Leukemia, 14, 1909, 10.1038/sj.leu.2401904 Grunwald, 2002, Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells, Cancer Res., 62, 6141 Han, 2005, Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer, Int. J. Cancer, 113, 109, 10.1002/ijc.20550 Haruta, 2000, A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1, Mol. Endocrinol., 14, 783, 10.1210/me.14.6.783 Hashemolhosseini, 1998, Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability, J. Biol. Chem., 273, 14424, 10.1074/jbc.273.23.14424 Hay, 2004, Upstream and downstream of mTOR, Genes Dev., 18, 1926, 10.1101/gad.1212704 Hemminki, 1998, A serine/threonine kinase gene defective in Peutz–Jeghers syndrome, Nature, 391, 184, 10.1038/34432 Hennessy, 2005, Exploiting the PI3K/AKT pathway for cancer drug discovery, Nat. Rev. Drug Discov., 4, 988, 10.1038/nrd1902 Holz, 2005, Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase, J. Biol. Chem., 280, 26089, 10.1074/jbc.M504045200 Houshmandi, 2007, All in the family: using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors, J. Cell Biochem., 102, 811, 10.1002/jcb.21506 Huang, 2003, Rapamycins: mechanism of action and cellular resistance, Cancer Biol. Ther., 2, 222, 10.4161/cbt.2.3.360 Huang, 2003, Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1), Mol. Cell, 11, 1491, 10.1016/S1097-2765(03)00180-1 Ilyin, 2003, Regulation and role of p21 and p27 cyclin-dependent kinase inhibitors during hepatocyte differentiation and growth, Am. J. Physiol Gastrointest. Liver Physiol., 285, G115, 10.1152/ajpgi.00309.2002 Inoki, 2005, Dysregulation of the TSC-mTOR pathway in human disease, Nat. Genet., 37, 19, 10.1038/ng1494 Inoki, 2003, TSC2 mediates cellular energy response to control cell growth and survival, Cell, 115, 577, 10.1016/S0092-8674(03)00929-2 Jacinto, 2003, Tor signalling in bugs, brain and brawn, Nat. Rev. Mol. Cell Biol., 4, 117, 10.1038/nrm1018 James, 2004, Phosphatidylinositol 3-kinase and mTOR signaling pathways regulate RNA polymerase I transcription in response to IGF-1 and nutrients, J. Biol. Chem., 279, 8911, 10.1074/jbc.M307735200 Janus, 2005, The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy, Cell Mol. Biol. Lett., 10, 479 Jastrzebski, 2007, Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function, Growth Factors, 25, 209, 10.1080/08977190701779101 Jenne, 1998, Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase, Nat. Genet., 18, 38, 10.1038/ng0198-38 Jiang, 2008, PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochim. Biophys. Acta, 1784, 150, 10.1016/j.bbapap.2007.09.008 Jimeno, 2007, Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy, Br. J. Cancer, 96, 952, 10.1038/sj.bjc.6603656 Johannessen, 2005, The NF1 tumor suppressor critically regulates TSC2 and mTOR, Proc. Natl. Acad. Sci. U.S.A., 102, 8573, 10.1073/pnas.0503224102 Johnson, 2005, RAS is regulated by the let-7 microRNA family, Cell, 120, 635, 10.1016/j.cell.2005.01.014 Katayama, 2007, Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein, Mol. Cancer Ther., 6, 2092, 10.1158/1535-7163.MCT-07-0148 Kawamata, 1998, The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines, Blood, 91, 561, 10.1182/blood.V91.2.561 Kisucka, 2001, Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells, Gen. Physiol. Biophys., 20, 439 Kolfschoten, 2005, A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity, Cell, 121, 849, 10.1016/j.cell.2005.04.017 Kunz, 1993, Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression, Cell, 73, 585, 10.1016/0092-8674(93)90144-F Lee, 2004, Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells, Cancer Res., 64, 8397, 10.1158/0008-5472.CAN-04-1612 Lee, 2005, Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line, Gynecol. Oncol., 97, 26, 10.1016/j.ygyno.2004.11.051 Lee, 2006, Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation, Biochem. Biophys. Res. Commun., 351, 1024, 10.1016/j.bbrc.2006.10.163 Li, 2003, Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas, Cancer Res., 63, 7443 Li, 2007, Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy, Cancer Cell, 12, 81, 10.1016/j.ccr.2007.06.005 Lin, 2003, Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway, Br. J. Cancer, 88, 973, 10.1038/sj.bjc.6600788 Lin, 2005, Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells, J. Urol., 174, 2022, 10.1097/01.ju.0000176476.14572.39 Liu, 2006, Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells, Free Radic. Biol. Med., 41, 1521, 10.1016/j.freeradbiomed.2006.08.003 Liu, 2007, AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway, Cancer Res., 67, 6325, 10.1158/0008-5472.CAN-06-4261 Liu, 2006, Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells, Dig. Liver Dis., 38, 310, 10.1016/j.dld.2006.01.012 Liu, 2006, Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT, Oncogene, 25, 3565, 10.1038/sj.onc.1209403 Lu, 2007, Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency, Clin. Cancer Res., 13, 5883, 10.1158/1078-0432.CCR-06-2837 Madhusudan, 2005, The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer, Cancer Treat. Rev., 31, 603, 10.1016/j.ctrv.2005.09.006 Mamane, 2006, mTOR, translation initiation and cancer, Oncogene, 25, 6416, 10.1038/sj.onc.1209888 Martin, 2000, 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers, Int. J. Biochem. Cell Biol., 32, 633, 10.1016/S1357-2725(00)00007-8 Mayer, 2006, Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases, Oncogene, 25, 6384, 10.1038/sj.onc.1209883 Mayer, 2004, mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability, Genes Dev., 18, 423, 10.1101/gad.285504 McClusky, 2005, A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer, Ann. Surg., 242, 584, 10.1097/01.sla.0000184224.55949.90 McCubrey, 2006, Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance, Adv. Enzyme Regul., 46, 249, 10.1016/j.advenzreg.2006.01.004 McCubrey, 2007, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochim. Biophys. Acta, 1773, 1263, 10.1016/j.bbamcr.2006.10.001 Meng, 2006, Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway, Cell Signal., 18, 2262, 10.1016/j.cellsig.2006.05.019 Merritt, 2006, Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations, Am. J. Med. Genet. A, 140, 1669, 10.1002/ajmg.a.31351 Mohi, 2004, Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs, Proc. Natl. Acad. Sci. U.S.A., 101, 3130, 10.1073/pnas.0400063101 Mollinedo, 2006, Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy, Drug Resist. Update, 9, 51, 10.1016/j.drup.2006.04.002 Mondesire, 2004, Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells, Clin. Cancer Res., 10, 7031, 10.1158/1078-0432.CCR-04-0361 Moretti, 2007, Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy, Drug Resist. Update, 10, 135, 10.1016/j.drup.2007.05.001 Nathan, 1999, Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer, J. Clin. Oncol., 17, 2909, 10.1200/JCO.1999.17.9.2909 Neri, 2003, The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells, Mol. Cancer Res., 1, 234 Neshat, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc. Natl. Acad. Sci. U.S.A., 98, 10314, 10.1073/pnas.171076798 Pacheco-Rodriguez, 2007, TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis, Cancer Res., 67, 10573, 10.1158/0008-5472.CAN-07-1356 Panner, 2005, mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells, Mol. Cell Biol., 25, 8809, 10.1128/MCB.25.20.8809-8823.2005 Pende, 2004, S6K1(−/−) /S6K2(−/−) mice exhibit perinatal lethality and rapamycin-sensitive 5’-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway, Mol. Cell Biol., 24, 3112, 10.1128/MCB.24.8.3112-3124.2004 Repasky, 2004, Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?, Trends Cell Biol., 14, 639, 10.1016/j.tcb.2004.09.014 Roberts, 2007, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer, Oncogene, 26, 3291, 10.1038/sj.onc.1210422 Rojo, 2007, 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis, Clin. Cancer Res., 13, 81, 10.1158/1078-0432.CCR-06-1560 Rosenwald, 1999, Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis, Oncogene, 18, 2507, 10.1038/sj.onc.1202563 Rousseau, 1996, The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth, Oncogene, 13, 2415 Roux, 2004, Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase, Proc. Natl. Acad. Sci. U.S.A., 101, 13489, 10.1073/pnas.0405659101 Rowinsky, 2004, Targeting the molecular target of rapamycin (mTOR), Curr. Opin. Oncol., 16, 564, 10.1097/01.cco.0000143964.74936.d1 Sabatini, 1994, RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs, Cell, 78, 35, 10.1016/0092-8674(94)90570-3 Salehi, 2006, Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer, Clin. Biochem., 39, 404, 10.1016/j.clinbiochem.2005.11.007 Sampson, 1994, The molecular genetics of tuberous sclerosis, Hum. Mol. Genet., 3, 1477, 10.1093/hmg/3.suppl_1.1477 Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex, Science, 307, 1098, 10.1126/science.1106148 Schubbert, 2007, Hyperactive Ras in developmental disorders and cancer, Nat. Rev. Cancer, 7, 295, 10.1038/nrc2109 Shaw, 2006, Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature, 441, 424, 10.1038/nature04869 Shi, 2002, Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779, Cancer Res., 62, 5027 Shuda, 2000, Enhanced expression of translation factor mRNAs in hepatocellular carcinoma, Anticancer Res., 20, 2489 Skinner, 2004, Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling, J. Biol. Chem., 279, 45643, 10.1074/jbc.M404097200 Skinner, 2004, Arsenite induces p70S6K1 activation and HIF-1alpha expression in prostate cancer cells, Mol. Cell Biochem., 255, 19, 10.1023/B:MCBI.0000007257.67733.3b Small, 2007, Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance, Cancer Res., 67, 4459, 10.1158/0008-5472.CAN-06-2644 Sonenberg, 1998, The mRNA 5′ cap-binding protein eIF4E and control of cell growth, Curr. Opin. Cell Biol., 10, 268, 10.1016/S0955-0674(98)80150-6 Sorrells, 1998, Detection of eIF4E gene amplification in breast cancer by competitive PCR, Ann. Surg. Oncol., 5, 232, 10.1007/BF02303778 Sorrells, 1999, Competitive PCR to detect eIF4E gene amplification in head and neck cancer, Head Neck, 21, 60, 10.1002/(SICI)1097-0347(199901)21:1<60::AID-HED8>3.0.CO;2-J Stephan, 2004, Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer, Clin. Cancer Res., 10, 6993, 10.1158/1078-0432.CCR-04-0808 Stromberg, 2004, Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone, Blood, 103, 3138, 10.1182/blood-2003-05-1543 Svensson, 2005, ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis, Oncogene, 24, 4370, 10.1038/sj.onc.1208626 Tabellini, 2005, Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells, J. Cell Physiol., 202, 623, 10.1002/jcp.20153 Tanaka, 2003, In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin, Gene Ther., 10, 1636, 10.1038/sj.gt.3302056 Tazzari, 2007, Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts, Leukemia, 21, 427, 10.1038/sj.leu.2404523 Thimmaiah, 2003, Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways, Cancer Res., 63, 364 Tokunaga, 2006, Activation of PI3K/Akt signaling and hormone resistance in breast cancer, Breast Cancer, 13, 137, 10.2325/jbcs.13.137 Tortora, 2007, Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematological malignancies, Drug Resist. Update, 10, 81, 10.1016/j.drup.2007.03.003 Tsang, 2007, Targeting mammalian target of rapamycin (mTOR) for health and diseases, Drug Discov. Today, 12, 112, 10.1016/j.drudis.2006.12.008 Tsurutani, 2005, Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy, Cancer Res., 65, 8423, 10.1158/0008-5472.CAN-05-0058 Vanderweele, 2005, Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate, Mol. Cancer Res., 3, 635, 10.1158/1541-7786.MCR-05-0063 Villedieu, 2006, Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment, Gynecol. Oncol., 101, 507, 10.1016/j.ygyno.2005.11.017 Wang, 2007, ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells, Cancer Res., 67, 11933, 10.1158/0008-5472.CAN-07-5185 Wang, 2006, Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells, Cancer Res., 66, 7864, 10.1158/0008-5472.CAN-04-4392 Wang, 2006, Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance, Cancer Res., 66, 8870, 10.1158/0008-5472.CAN-06-1280 Ward, 2003, Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents, Curr. Opin. Pharmacol., 3, 426, 10.1016/S1471-4892(03)00078-X White, 1997, Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control?, Trends Biochem. Sci., 22, 77, 10.1016/S0968-0004(96)10067-0 Wolthuis, 1999, Ras caught in another affair: the exchange factors for Ral, Curr. Opin. Genet. Dev., 9, 112, 10.1016/S0959-437X(99)80016-1 Wu, 2005, Overcoming cisplatin resistance by mTOR inhibitor in lung cancer, Mol. Cancer, 4, 25, 10.1186/1476-4598-4-25 Yamasaki, 2007, Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt, Cancer Res., 67, 5779, 10.1158/0008-5472.CAN-06-3020 Yeung, 1994, Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene, Proc. Natl. Acad. Sci. U.S.A., 91, 11413, 10.1073/pnas.91.24.11413 Yu, 2006, Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy, Drug Resist. Update, 9, 19, 10.1016/j.drup.2006.03.001 Yu, 2008, Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death, Int. J. Cancer, 122, 433, 10.1002/ijc.23049 Yuan, 2003, AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance, J. Biol. Chem., 278, 23432, 10.1074/jbc.M302674200 Zhao, 2006, Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells, J. Surg. Res., 136, 325, 10.1016/j.jss.2006.06.031 Zhong, 2004, SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway, Biochem. Biophys. Res. Commun., 324, 471, 10.1016/j.bbrc.2004.09.082 Zhou, 2007, Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells, Carcinogenesis, 28, 28, 10.1093/carcin/bgl085 Zhuang, 2006, Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential, Mol. Cancer Res., 4, 843, 10.1158/1541-7786.MCR-06-0118